New Study Results Published – Lilly GZGI

Two new phase 2 studies suggest that the investigational drug orforglipron, developed by Eli Lilly, shows promise in the treatment of obesity and type 2 diabetes. Currently, GLP-1 agonists (a class of medications utilized in the treatment of type 2 diabetes mellitus and obesity) approved for these conditions are administered via under the skin injection,

Are Autoimmune Diseases Becoming More Common?

A new population-based study, involving 22 million people, shows that autoimmune disorders now affect around one in ten individuals. These conditions pose a huge burden on individuals and upon wider society, and currently represent an enormous unmet clinical need. Autoimmune diseases are a group of disorders characterized by an abnormal immune response, where the immune